Non-alcoholic fatty liver disease (NAFLD) is an increasingly important cause of chronic liver disease globally. Similar to metabolic syndrome and obesity, NAFLD is associated with alternations in the gut microbiota and its related biological pathways. While the exact pathophysiology of NAFLD remains largely unknown, changes in intestinal inflammation, gut permeability, energy harvest, anaerobic fermentation and insulin resistance have been described. In this chapter, we review the relationship between the gut microbiota, obesity and NAFLD, and highlight potential ways to modify the gut microbiota to help managing NAFLD patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-981-10-8684-7_9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease.
Ann Pharmacother
March 2025
Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Objective: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD).
Data Sources: A literature review was conducted using the search terms , , , , , and on PubMed (from January 1, 2019, through February 1, 2025), National Institutes of Health (NIH) (from January 1, 2019, through February 1, 2025), Scopus (from January 1, 2019, through February 1, 2025), and the World Health Organization (WHO) data.
Study Selection And Data Extraction: All relevant clinical trials, review articles, package inserts, and guidelines evaluating clinically relevant evidence regarding the therapeutic potential of GLP-1 agonists in MASLD were considered for inclusion.
Carotenoids Improve Obesity and Fatty Liver Disease via Gut Microbiota: A Narrative Review.
Food Sci Nutr
March 2025
Department of Nutrition, Food Sciences and Clinical Biochemistry, School of Medicine, Social Determinants of Health Research Center Gonabad University of Medical Sciences Gonabad Iran.
Carotenoids are natural micronutrients found in plants and microorganisms, but not synthesized by animals. Carotenoids show various biological activities, including antioxidant properties, regulation of cell growth, and modulation of gene expression and immune responses. The rising global incidence of fatty liver disease (FLD) and obesity highlights the importance of carotenoids in chronic progressive conditions.
View Article and Find Full Text PDFMechanisms underpinning the effect of exercise on the non-alcoholic fatty liver disease: review.
EXCLI J
February 2025
Molecular Hepatology Section, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Non-alcoholic Fatty Liver Disease (NAFLD) - whose terminology was recently replaced by metabolic liver disease (MAFLD) - is an accumulation of triglycerides in the liver of >5 % of its weight. Epidemiological studies indicated an association between NAFLD and reduced physical activity. In addition, exercise has been shown to improve NAFLD independently of weight loss.
View Article and Find Full Text PDFNoninvasive identification of metabolic dysfunction-associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study.
Expert Rev Gastroenterol Hepatol
March 2025
Novo Nordisk Inc, Plainsboro, NJ, USA.
Background: Using common clinical parameters, we aimed to noninvasively identify and predict metabolic dysfunction - associated steatohepatitis (MASH)/MASH with clinically significant fibrosis.
Research Design And Methods: Patients aged ≥ 18 with electronic health record (EHR) documented liver function tests and liver biopsies between 2016-2021 were retrospectively identified from the Geisinger Health System Research Liver Registry. MASH cases were confirmed using the nonalcoholic fatty liver disease (NAFLD) activity score.
US Liver Imaging Reporting and Data System Version 2017: A Systematic Review and Meta-Analysis.
Radiology
March 2025
Department of Radiology, Columbia University Irving Medical Center, 622 W 168th St, New York, NY 10032.
Background The US Liver Imaging Reporting and Data System (LI-RADS) includes an assessment category (US-1, negative; US-2, subthreshold; and US-3, positive) and a visualization score reflecting image quality (VIS-A, no or minimal limitations; VIS-B, moderate limitations; and VIS-C, severe limitations). The US-3 and VIS-C impact patient treatment. Purpose To establish the distributions of categories and visualization scores, estimate the proportions of hepatocellular carcinoma (HCC) and overall malignancy in the US-3 category, and identify variables associated with the VIS-C score by conducting a meta-analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!